Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Lemonade Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Lemonade Inc trades at $43.49 (market cap $3.46B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 2.5× Lemonade Inc's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Lemonade Inc for 27 Days on average.
| HNGE | LMND | |
|---|---|---|
Market Cap | $8.48B | $3.46B |
Volume | 879,799 | 1,011,472 |
Sector | Health | Financials |
52-Week High | $105.14 | $96.57 |
52-Week Low | $31.17 | $43.86 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $8.10B | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Lemonade (LMND) trades at $43.86, down 2.86% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to show strong revenue growth, with 2025 revenue reaching $738 million and improving margins, though it remains unprofitable with a net loss of $166 million. Recent expansion into Alaska and Kentucky, along with AI-driven efficiency improvements, supports the company's path toward EBITDA profitability by late 2026.
While Lemonade shows promising growth and margin improvement, the stock faces near-term technical pressure and persistent profitability challenges. The consensus price target of $67 offers significant upside potential, but investors must weigh expansion opportunities against ongoing losses and competitive pressures in the insurtech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
